Literature DB >> 12793621

Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management.

Laura Pimentel1, Scott J McPherson.   

Abstract

Pneumonia is one of the most common conditions for which patients seek emergency care. It is a challenging infection in that the spectrum of illness ranges from the nontoxic patient appropriate for outpatient antibiotics to the critically ill patient requiring intensive care hospitalization. Current data and diagnostic technology provide the emergency physician with the tools for an appropriately rapid evaluation and consideration of the differential diagnosis. Key critical thinking and application of published findings allow for intelligent empirical antibiotic treatment and risk stratification for the best disposition. Although antibiotic-resistant organisms increasingly are being identified, patients continue to benefit from early institution of standard ED treatment. Coverage for atypical organisms improves patient response and outcome. Finally, identification and treatment of the complications of pneumonia and accompanying sepsis must be considered by the ED physician when evaluating critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12793621     DOI: 10.1016/s0733-8627(03)00019-1

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  3 in total

Review 1.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

Review 2.  Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

3.  A simple screening tool for identification of community-acquired pneumonia in an inner city emergency department.

Authors:  Ambreen Khalil; Gabor Kelen; Richard E Rothman
Journal:  Emerg Med J       Date:  2007-05       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.